Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation

Liver Transplantation

Volumn 18, Issue 5, 2012, Pages 514-523

  Laryea, Marie A ^a   Watt, Kymberly D ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIBODY TITER; DISEASE COURSE; DNA DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MONOTHERAPY; ORGAN DONOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT DURATION; VACCINATION;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS;

EID: 84860210908     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23408     Document Type: Review

References (62)

1. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS Jr, et al.; for NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823-1833.
2. Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA,. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 2011; 17: 955-962.
3. Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS,; for NIH HBV-OLT Study Group. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl 2007; 13: 1137-1144.
4. Yasunaka T, Takaki A, Yagi T, Iwasaki Y, Sadamori H, Koike K, et al. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int 2011; 5: 918-926.
5. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 86-95.
6. Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55: 587-593.
7. Xie SB, Zhu JY, Ying Z, Zeng LJ, Chao M, Lu MQ,. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Transplantation 2010; 90: 786-790.
8. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890-1899.
9. Jiang L, Yan LN,. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16: 2468-2475.
10. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
11. König V, Hopf U, Neuhaus P, Bauditz J, Schmidt CA, Blumhardt G, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994; 58: 553-559.
12. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H,. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
13. Shouval D, Samuel D,. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195.
14. Germer JJ, Charlton MR, Ishitani MB, Forehand CD, Patel R,. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. Am J Transplant 2003; 3: 743-753.
15. Hwang S, Ahn CS, Song GW, Kim KH, Moon DB, Oh HB, et al. Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on. Liver Transpl 2011; 17: 456-465.
16. Katz LH, Tur-Kaspa R, Guy DG, Paul M,. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Cochrane Database Syst Rev 2010: CD006005.
17. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G,. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700.
18. Chen J, Yi L, Jia JD, Ma H, You H,. Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review. J Gastroenterol Hepatol 2010; 25: 872-879.
19. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
20. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M,. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203-1208.
21. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H,. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433.
22. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW,; for Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
23. Testino G, Borro P, Sumberaz A,. Prophylaxis of hepatitis B virus recurrence after liver transplantation. J Gastrointestin Liver Dis 2009; 18: 139-141.
24. Singham J, Greanya ED, Lau K, Erb SR, Partovi N, Yoshida EM,. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol 2010; 9: 166-171.
25. Yahyazadeh A, Beckebaum S, Cicinnati V, Klein C, Paul A, Pascher A, Neuhaus R,. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int 2011; 24: 441-450.
26. Iacob S, Hrehoret D, Matei E, Dorobantu B, Gangone E, Gheorghe L, Popescu I,. Costs and efficacy of "on demand" low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis 2008; 17: 383-388.
27. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758.
28. Weber NK, Forman LM, Trotter JF,. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010; 55: 505-509.
29. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS,. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-381.
30. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ,. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 434-439.
31. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817.
32. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A,. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20: 206-210.
33. Seehofer D, Rayes N, Naumann U, Neuhaus R, Müller AR, Tullius SG, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001; 72: 1381-1385.
34. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Böker KHW,. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
35. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M,. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258.
36. Yoshida H, Kato T, Levi DM, Regev A, Madariaga JR, Nishida S, et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007; 21: 166-171.
37. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al.; for Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360.
38. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-1089.
39. Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F,. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-1261.
40. Pawlotsky JM,. EASL clinical practice guidelines. J Hepatol 2009; 50: 243.
41. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10: 321-327.
42. Jiménez-Pérez M, Sáez-Gõmez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-Lõpez JM,. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 2010; 42: 3167-3168.
43. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E,. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
44. Bienzle U, Günther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, Neuhaus P,. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38: 811-819.
45. Rosenau J, Hooman N, Rifai K, Solga T, Tillmann HL, Grzegowski E, et al. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int 2006; 19: 828-833.
46. Di Paolo D, Lenci I, Cerocchi C, Tariciotti L, Monaco A, Brega A, et al. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl Int 2010; 23: 1105-1112.
47. Stärkel P, Stoffel M, Lerut J, Horsmans Y,. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 2005; 11: 1228-1234.
48. Ishigami M, Kamei H, Nakamura T, Katano Y, Ando H, Kiuchi T, Goto H,. Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol 2011; 46: 367-377.
49. Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J, et al. Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: not an effective measure in transplant recipients. Hepatol Res 2009; 39: 7-13.
50. Cholongitas E, Papatheodoridis GV, Burroughs AK,. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272-279.
51. Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002; 73: 1598-1602.
52. Saab S, Waterman B, Chi AC, Tong MJ,. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl 2010; 16: 300-307.
53. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV,. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-1190.
54. Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, et al. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol; doi:10.1016/j.jhep.2011.09.016.
55. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M,. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-928.
56. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820.
57. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
58. Féray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynès M, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998; 128: 810-816.
59. Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006; 80: 2654-2664.
60. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al.; for Collaborative Antiviral Study Group. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941-949.
61. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006; 12: 1381-1389.
62. Houghton M,. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239: 99-108.